Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000171.xml
Dtsch Med Wochenschr 2011; 136(40): 2029-2032
DOI: 10.1055/s-0031-1286387
DOI: 10.1055/s-0031-1286387
Pneumologie | Commentary
Pneumologie, Onkologie
© Georg Thieme Verlag KG Stuttgart · New York
Pneumologische Onkologie
Thoracic oncologyFurther Information
Publication History
Publication Date:
28 September 2011 (online)
![](https://www.thieme-connect.de/media/dmw/201140/lookinside/thumbnails/10.1055-s-0031-1286387-1.jpg)
Schlüsselwörter
Lungenkrebs - Früherkennung - EGFR-Mutationen
Keywords
lung cancer - early detection - EGFR mutations
Literatur
- 1 Becker G, Hatami I, Xander C. et al . Palliative cancer care: an epidemiologic study. J Clin Oncol. 2011; 29 646-650
- 2 Cappuzzo F, Ciuleanu T, Stelmakh L. et al . Erlotinib as maintenance treatment in advanced non-small-cell lung cancer. Lancet Oncol. 2010; 11 521-529
- 3 Cataldo V D, Gibbons D L, Perez-Soler R, Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011; 364 947-955
- 4 Ciuleanu T, Brodowicz T, Zielinski C. et al . Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009; 374 1432-1440
- 5 Cohen M H, Johnson J R, Chattopadhyay S, Tang S, Justice R, Sridhara R, Pazdur R. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC). Oncologist. 2010; 15 1344-1351
- 6 Davidoff A J, Tang M, Seal B, Edelman M J. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28 2191-2197
- 7 Fidias P M, Dakhil S R, Lyss A P. et al . Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27 591-598
- 8 Goeckenjan G, Sitter H, Thomas M. et al . [Prevention, diagnosis, therapy, and follow-up of lung cancer]. Pneumologie. 2010; 64 Suppl 2 e1-164
- 9 Goldstraw P, Crowley J, Chansky K. et al . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2 706-714
- 10 Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol. 2009; 27 4232-4235
- 11 Jackman D, Pao W, Riely G J. et al . Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010; 28 357-360
- 12 Jemal A, Bray F, Center M M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61 69-90
- 13 Kris M G, Johnson B E, Kwiatkowski D J. et al . Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). J Clin Oncol. 2011; 29 Suppl: abstr CRA7506
- 14 Kwak E L, Bang Y J, Camidge D R. et al . Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363 1693-1703
- 15 Maemondo M, Inoue A, Kobayashi K. et al . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362 2380-2388
- 16 Mitsudomi T, Morita S, Yatabe Y. et al . Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405). Lancet Oncol. 2010; 11 121-128
- 17 Mok T S, Wu Y L, Thongprasert S. et al . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361 947-957
- 18 Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12 175-180
- 19 Quoix E A, Oster J, Westeel V. et al . Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89. J Clin Oncol. 2010; 28 Suppl 18s, abstr 2
- 20 Sequist L V, Heist R S, Shaw A T. et al . SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. J Clin Oncol. 2011; 29 Suppl abstr 7518
- 21 Soon Y Y, Stockler M R, Askie L M, Boyer M J. Duration of chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27 3277-3283
- 22 Stinchcombe T E, Socinski M A. Maintenance therapy in advanced non-small cell lung cancer: current status and future implications. J Thorac Oncol. 2011; 6 174-182
- 23 Temel J S, Greer J A, Muzikansky. et al . Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010; 363 733-742
- 24 The National Lung Screening Trial Research Team . Reduced Lung-Cancer Mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365 395-409
- 25 Travis W D, Brambilla E, Noguchi M. et al . International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6 244-285
- 26 Vogelmeier C, Worth H, Pfeifer M. et al . [Joint statement of the German Respiratory Society and the German Roentgenological Society on the early detection of lung cancer by low-dose CT]. Pneumologie. 2011; 65 5-6
Univ.-Prof. Dr. med. Rainer Wiewrodt
Klinik und Poliklinik für Innere
Medizin A mit den Schwerpunkten Hämatologie, Onkologie
und Pneumologie
Universitätsklinikum Münster
Albert-Schweitzer-Campus 1, Gebäude A1
48149
Münster
Phone: 0251/8344803
Fax: 0251/8344804
Email: rainer.wiewrodt@ukmuenster.de